Baird raised its price target on Celgene citing its late stage pipeline and expectations for clarity on Revlimed's EU front-line approval status. Shares are Outperform rated.
Asian stocks fell to one-month lows on Friday and the yen rebounded broadly as extreme volatility in the Nikkei …